Nimish Muzumdar

Nimish Muzumdar

SVP, PRESIDENT, NORTH AMERICA

Nimish Muzumdar serves as SVP and President, North America and is responsible for leading the United States and Canada commercial teams and executing the region’s long-term growth strategy.  He has more than 25 years of experience in US retail pharmacy and hospital channels and a track record of driving growth in the highly competitive generic drugs industry. Most recently, he served as Senior Vice President & Head, Generics (Retail, Institutional, Hospitals & Clinics) at Sandoz, where he helped shape the organization’s commercial strategy, culture, and operational foundation for long-term success. Previously in his decade-plus at Sandoz, Nimish served as Director, Generics Oncology & Injectables; Executive Director, Generics Oncology & Injectables; Executive Director, Retail Generics; and Vice President & Head of Generics. Prior to Sandoz, he held marketing roles of increasing leadership responsibility for Ranbaxy USA, Watson Laboratories, and Dr. Reddy’s Laboratories.

Nimish holds a Bachelor of Science – Pharmacy from the University of Mumbai and an MBA from New York Institute of Technology.

    Forward Looking Statement

    The information included on this website and other information provided from time to time through webcasts, conference calls, securities analyst meetings, road show presentations, investor conferences, transcripts, newsletters and similar events and communications contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws, based on current expectations and assumptions that involve risks and uncertainties. If the risks or uncertainties ever materialize or the assumptions prove incorrect, the results of embecta may differ materially from those expressed or implied by such forward-looking statements and assumptions.These statements use words such as "will," "plan," "expect," "anticipate," "estimate," "next," "project," "potential," "continue," "expand" and "grow" and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance and statements regarding our business strategy, impact of mergers and acquisitions,future product development, regulatory clearances and approvals, competitive position and expenditures.These statements are based on current assumptions and expectations of future events at the time they are made and thus are inherently subject to uncertainty.

    All such statements are based upon current expectations of embecta and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Many of these risks and uncertainties are beyond the company's control. For a discussion of certain factors that could cause our actual results to differ from our expectations in any forward-looking statements see our latest Annual Report on Form 10-K and other filings with the SEC. embecta expressly disclaims any undertaking to update or revise any forward looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.